Outstanding Vietnamese Scientists Honored at the Alexandre Yersin Award

  • News

We were incredibly proud as scientists from Gene Solutions and Institute of Medical Genetics continued to be honored at the prestigious 4th Alexandre Yersin Award (2023-2024). This is not just a title, but also a recognition of the relentless efforts of Vietnamese scientists in research and development in medicine. Furthermore, the success of the scientists from Gene Solutions and the Institute of Medical Genetics is a clear testament to the strong development of the Vietnamese medical field. 

Congratulations to the Vietnamese scientists who won the “Encouragement Prizes”:  

👤 Dr. Tran Le Son (Ph.D.) and Nguyen Van Thien Chi (MSc) with their report ” Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization”.  

➡️ See details at: https://helvietmed.org/wp-content/uploads/2024/05/Le-Son-Tran-et-al.eLife_2023.pdf 

👤 Nguyen Hoang Van Anh (MSc) with the report ” Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer”  

➡️ See details at: https://helvietmed.org/wp-content/uploads/2024/05/Molecular-Oncology-Nguyen-Hoang-Genetic-landscape-and-personalized-tracking-of-tumor-mutations-in-Vietnamese.pdf 

————————- 

Alexandre Yersin is best known for discovering Yersinia pestis, the bacterium responsible for the bubonic plague, and for his lasting contributions to Vietnam’s medical, educational, and agricultural development, where his transdisciplinary approach and compassion for the local population left a profound legacy. 

The Alexandre Yersin Award for Outstanding Papers was established by the Swiss-Vietnamese Medical Association (HELVIETMED) to honor Vietnamese scientists who have made significant contributions to medical literature, helping build Vietnam’s reputation in the international medical research community through peer-reviewed publications. 

————————- 

SPOT-MAS was conducted at the first and only NGS laboratory in Vietnam that meets CAP standards – the gold standard for quality management in leading laboratories in the United States. Visit our website to read more information about our oncology portfolio: https://genesolutions.com/our-test 

#MGJGeneSolutionsGroup #CAPNGS #MGJCAP #CAPAccredited #genesolutions #ctDNA #Spotmas #Ktrack #NIPT #Alexandre #Yersin #HELVIETMED

Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More